Niacin (Flush)
Best-in-class: Niacin (Flush)
The flushing form of vitamin B3, used at higher doses for cholesterol/lipid management (raises HDL, lowers Lp(a)) — distinct from non-flushing niacinamide.
Niacin (Flush) quick facts
| Suggested dose | Start low (100 mg) and titrate; higher lipid doses need medical supervision. |
| How often | Daily |
| Who it's for | Lipid management (HDL/Lp(a)) — under guidance. |
The single clearest example in cardiology that moving a number is not the same as changing an outcome. Niacin improves the lipid panel impressively, and both AIM-HIGH and HPS2-THRIVE found no event reduction on top of a statin — with net harm, including new-onset diabetes and infections. It remains one of the only Lp(a)-lowering options, which is why it has not disappeared entirely, but it needs a prescriber rather than a supplement decision.
How Niacin (Flush) actually works
Nicotinic acid at pharmacological doses inhibits hormone-sensitive lipase in adipose tissue, reducing free fatty acid flux to the liver and therefore VLDL production. It raises HDL more than anything else available and is one of very few agents that lowers Lp(a). The flush comes from GPR109A activation in skin causing prostaglandin D2 release — unrelated to the lipid effect, which is why the non-flushing form also lacks the benefit.
Where to get Niacin (Flush)
Find Niacin (Flush) on iHerb →The evidence for Niacin (Flush)
Graded by what exists behind each claim.
✅ Clinically validated
- Raises HDL and lowers triglycerides and Lp(a) at pharmacologic doses (well-established lipid effects).
- The characteristic 'flush' is a harmless prostaglandin response.
📊 Correlative data
- Decades of prescription use at gram doses gave it real population exposure and a clear picture of the flush, the glucose effect and the hepatotoxicity risk of sustained-release forms. The outcome trials then undercut it — AIM-HIGH and HPS2-THRIVE found no cardiovascular benefit added to statins, with more adverse events.
🧪 Theoretical / extrapolated benefits
- Cardiovascular-outcome benefit of niacin is debated despite the lipid changes — use thoughtfully.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Niacin (Flush) actually does
Nicotinic acid has two entirely separate jobs and the lipid job is the one that needs a thousand times the vitamin dose. As a vitamin it is a precursor for nicotinamide adenine dinucleotide by way of the Preiss-Handler pathway, and the requirement is satisfied at roughly 16 mg a day, or less if dietary tryptophan is generous Hrubša 2022. As a lipid agent it is used at 1 to 3 grams a day. Nothing about the second use is a vitamin effect, and a page that treats the two as one substance has already made the mistake.
The lipid effect starts in the fat cell, not in the liver. Nicotinic acid is an agonist at the G protein-coupled receptor GPR109A on the adipocyte, and receptor engagement lowers cyclic AMP, which suppresses hormone-sensitive lipase and cuts the release of free fatty acids into the portal circulation. Less substrate reaching the hepatocyte means less triglyceride assembled onto apolipoprotein B, and less very low density lipoprotein secreted. Triglycerides fall first and the rest of the panel follows from that.
The HDL rise is a clearance effect, and this is where the surrogate gets interesting. Nicotinic acid slows hepatic uptake of apolipoprotein A-I through the beta-chain of ATP synthase, so the particle circulates longer. HDL cholesterol on a lipid panel is a concentration, and a concentration rises when removal slows just as readily as when production or reverse cholesterol transport improves. The number moved; the traffic did not necessarily.
The flush is a different receptor population and a prostaglandin. The same GPR109A on Langerhans cells and keratinocytes drives cyclooxygenase-dependent release of prostaglandin D2 and E2, which dilate cutaneous vessels — the mechanism was established in receptor-null mice, which do not flush Benyo 2005. That is why aspirin 30 minutes beforehand blunts it and why tolerance develops within a week or two of steady dosing.
And there is a terminal metabolite that nobody was watching. Excess nicotinic acid is methylated and then oxidized to N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-3-carboxamide, the second of which is associated with major adverse cardiovascular events across three cohorts and drives vascular cell adhesion molecule 1 expression through an inflammatory pathway Ferrell 2024. That is a mechanism by which the surplus, rather than the vitamin, does harm — and it arrived four decades after the lipid indication.
Cell, rodent, human — and where it stops
The dish-to-human chain on lipids is complete and the human-to-outcome chain is where it collapses.
In cells and rodents the receptor pharmacology is clean. GPR109A was deorphanized as the nicotinic acid receptor, the antilipolytic effect reproduces in isolated adipocytes, and the flush disappears in receptor-null animals Benyo 2005. There is no ambiguity about what the molecule binds or what happens next.
In humans the lipid panel does exactly what the mechanism predicts. Gram doses raise HDL cholesterol by roughly 15 to 35 percent, cut triglycerides by 20 to 50 percent and lower lipoprotein(a) by 20 to 30 percent, which is more than almost anything else available. For thirty years that was treated as sufficient, because a better lipid panel was assumed to be a better outcome.
Then the endpoint trials on a statin background reported, and the assumption failed. Adding extended-release nicotinic acid to well-controlled low density lipoprotein cholesterol produced no reduction in cardiovascular events, with excess adverse effects including new-onset diabetes, infection and bleeding; the cardiology review of supplemental vitamins and minerals places nicotinic acid among the interventions that move a marker without moving an outcome Jenkins 2021. The obstacle to transfer is not dose and it is not adherence. It is that HDL cholesterol was a marker of risk and was never shown to be a lever on it.
The most recent human evidence goes further than null. Measuring the terminal metabolites directly rather than the lipid panel, higher circulating 4PY tracked with more events across independent cohorts, and the same metabolite induced vascular inflammation in a model system Ferrell 2024. If that holds, the trials were not diluted by a small effect; they were averaging a lipid benefit against a metabolite harm.
Note what does NOT transfer from the amide. Nicotinamide at 500 mg twice daily reduced new keratinocyte skin cancers in a phase 3 trial Chen 2015. Nicotinamide does not bind GPR109A, does not flush and does not move lipids. Evidence for one is not evidence for the other, and the bottles sit next to each other.
Niacin (Flush) — which form, and does it matter
Three things are sold as niacin and only one of them lowers lipids. Nicotinic acid is the lipid agent. Nicotinamide is the amide, is the form in most B-complex products, and has no lipid effect at any dose. Inositol hexanicotinate, marketed as flush-free niacin, is an ester of six nicotinic acid molecules on an inositol core that is hydrolyzed slowly and incompletely; it does not flush because it does not release enough free nicotinic acid to engage the receptor, and for the same reason it has not shown the lipid effect the buyer is paying for. Flush-free is not a gentler version of the drug. It is a different compound that fails to become it.
The exposure question is a release-rate question and it has a toxicity attached. Immediate-release nicotinic acid reaches peak plasma concentration in about 30 to 60 minutes with a plasma half-life of roughly 20 to 45 minutes, which is why the flush is sharp and why twice or three times daily dosing was used. Absorption is nearly complete, and first-pass metabolism in the liver splits into a low-capacity amidation pathway that saturates and a conjugation pathway that does not.
Which pathway carries the dose is what decides whether the liver is injured. At gram doses the amidation route saturates and more of the compound is handled by glucuronidation and excreted; sustained-release products, by feeding the drug in slowly, keep the amidation route in play for longer and generate more of the amide metabolites implicated in hepatotoxicity. That is the reason sustained-release nicotinic acid carries more reports of transaminase elevation and fulminant hepatitis than the immediate-release form at equal daily dose, and it is the opposite of the usual expectation that slower is safer.
Renal clearance carries the unmetabolized fraction, and the metabolite that matters is not measured anywhere. The 2PY and 4PY pyridones are renally cleared and accumulate in chronic kidney disease. No commercial panel reports either one, so the exposure most closely tied to harm in the recent work is invisible to the person taking the product Ferrell 2024.
A practical consequence of all of this. A label that says 500 mg niacin tells the reader neither which molecule is inside nor how fast it is released, and both of those decide the effect and the risk. The ingredient line, not the front of the bottle, is where the answer is.
What would have to be true, and how you would know it was not
1. The lipid panel will move and it will move fast. On 1 to 2 g of immediate-release nicotinic acid daily, predict triglycerides down and HDL cholesterol up within 6 to 8 weeks, with Lp(a) falling over 12 weeks. Retest the lipid panel and Lp(a) at 12 weeks. If HDL cholesterol does not rise at all, the product is almost certainly nicotinamide or inositol hexanicotinate rather than nicotinic acid.
2. ApoB is the read-out that decides whether the panel change was worth anything. Particle number, not HDL cholesterol, is the quantity that tracks with risk. Predict a modest fall in ApoB if triglycerides were high to begin with, and no meaningful fall in somebody whose triglycerides were already normal. A rising HDL cholesterol with an unchanged ApoB is the signature of this whole chapter of cardiology.
3. The prediction that cuts against the product. Predict that adding nicotinic acid to an adult whose LDL cholesterol is already at target on a statin produces no reduction in cardiovascular events, because that is what the endpoint trials returned Jenkins 2021. A modern trial showing event reduction on top of a statin would falsify this page. So would a cohort study in which circulating 4PY failed to associate with events Ferrell 2024.
4. Predict fasting glucose and HbA1c drift upward, and set a threshold in advance. Nicotinic acid raises insulin resistance by the same antilipolytic mechanism that lowers triglycerides, and new-onset diabetes was one of the excess harms in the outcome trials. Check fasting insulin and HbA1c at baseline and at 12 weeks; a rise of 0.2 percentage points or more in HbA1c is a reason to stop rather than to add.
5. Predict transaminases stay normal on immediate-release and watch them anyway. Baseline ALT, AST and uric acid, repeated at 6 and 12 weeks and after any dose increase. Hepatotoxicity in this class is dose-related and form-related rather than idiosyncratic, so a rising ALT on a sustained-release product is a predictable event and not bad luck.
What nobody has tested yet
Nobody has repeated the outcome question with the metabolite in hand. The endpoint trials measured lipids, not pyridones. Whether a person who lowers triglycerides on nicotinic acid without generating high 4PY has a different outcome from one who does is the obvious next study, has not been done, and would decide whether the drug is useless or merely mistargeted Ferrell 2024.
Nobody has assayed the flush-free shelf. Inositol hexanicotinate is sold on the strength of nicotinic acid's lipid reputation, and there is no published survey that buys a dozen flush-free products and reports free nicotinic acid released per serving under simulated gastric and intestinal conditions. That is a one-laboratory experiment and its absence lets the category continue as it is.
Nobody knows the threshold dose for the pyridone signal. The recent cohort work is in people with ordinary dietary and fortification exposure, not in people taking gram doses, so the dose-response between supplemental nicotinic acid and 4PY has not been characterized in humans. Whether a 100 mg starter dose generates any excess at all is unresolved.
And nobody has tested the low-dose lipid claim. Products sold at 100 to 500 mg sit below every dose used in the lipid trials and above every dose needed as a vitamin. No randomized trial has asked what that intermediate range does to ApoB, which means the most commonly purchased dose is the least studied one.
Niacin (Flush) — its own safety story, not its category's
The flush is harmless and the syncope is not. Cutaneous vasodilation can drop blood pressure enough to cause fainting, particularly on an empty stomach, after alcohol, in a hot shower, or when the dose is escalated quickly — a documented presentation with an over-the-counter product Huang 2023. The injury in these cases comes from the fall, not from the drug.
Hepatotoxicity is the reason this molecule needs supervision at lipid doses. Transaminase elevation is dose-related and clusters on sustained-release preparations, and fulminant hepatic failure has been reported after patients switched from immediate-release to an equal dose of a sustained-release product on the assumption that the forms were interchangeable. They are not.
Three metabolic effects that are easy to miss because they are silent. Insulin resistance rises, which matters most in people already at risk of diabetes. Uric acid rises through competition for renal tubular secretion, which can precipitate gout. And nicotinic acid can activate peptic ulcer disease. None of these announces itself; all of them are visible on ordinary bloodwork.
The interactions worth naming. Statins plus gram-dose nicotinic acid carries an increased myopathy signal, and the combination is where most of the reported rhabdomyolysis in this class sits. Antihypertensives and alpha blockers add to the vasodilatory drop. Alcohol worsens both flush and hepatic risk. Aspirin taken beforehand blunts the flush by blocking the prostaglandin step Benyo 2005, which is useful and also removes the feedback that would otherwise stop somebody escalating too fast.
Who should not be taking this at a lipid dose without supervision. Anyone with active liver disease or unexplained transaminase elevation, anyone with an arterial bleeding risk, anyone with gout, and anyone pregnant. Gram-dose nicotinic acid is a prescription-strength intervention sold over a counter, which is the actual safety story on this page. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.
Sources read for this page
- Benyo Z, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. Journal of Clinical Investigation 2005 · PMID 16322797
- Ferrell M. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat Med 2024 · PMID 38374343
- Jenkins DJA. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar. J Am Coll Cardiol 2021 · PMID 33509399
- Huang J. Niacin-Induced Syncope in a Middle-Aged Male: When an Over-the-Counter Vitamin Goes Wrong. Cureus 2023 · PMID 38222212
- Hrubša M. Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5. Nutrients 2022 · PMID 35276844
- Chen AC, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.. New England Journal of Medicine 2015 · PMID 26488693
How you would know if it worked
These are the markers that recommend this product on their own pages, so they are the ones that should move if it is doing what it is sold for.
- Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — Niacin raises HDL but lacks outcome benefit Retest: Every 3–6 months on androgens; annually otherwise.
- Lipoprotein(a) — Lp(a) — Niacin lowers it modestly (~20%) but hasn't shown outcome benefit and has side effects Retest: Once in a lifetime is sufficient unless kidney or thyroid status changes markedly.
- Apolipoprotein A-1 — Omega-3s, niacin (raises HDL but no proven outcome benefit) Retest: Every 3–6 months on androgens.
The cheapest panel carrying Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) and at least one other of these is Keto or Carnivore — the Numbers That Move, at $143 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Niacin (Flush) — safety & side effects
- The flush is expected: intense warmth, redness and itching over the face and chest, 15–30 minutes in, lasting up to an hour. It is harmless, it diminishes with regular use, and taking it with food or a low-dose aspirin blunts it.
- At the doses used for lipids (1–3 g), niacin is a drug. Liver toxicity, raised blood glucose, raised uric acid and gout flares are all real. Sustained-release forms are the most hepatotoxic.
- The large outcome trials did not show benefit when added to a statin, and showed harm. That is worth knowing before starting it for cholesterol.
- Avoid in liver disease, active peptic ulcer and uncontrolled gout. Monitor liver enzymes, glucose and uric acid if you use it at these doses.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Niacin (Flush) in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Niacin (Flush)
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Raises HDL and lowers triglycerides — the reason it's taken |
| Uric Acid | Niacin raises it and can precipitate gout |
| HbA1c (Hemoglobin A1c) | It worsens glucose control, which offsets the lipid benefit |
| Comprehensive Metabolic Panel (CMP) | Liver, especially with sustained-release forms |
The Real Cardiovascular Risk panel covers these in one order — 9 markers, $187.60 with the discount applied.
Check results you already have → · All 103 markers A–Z
Niacin (Flush) — frequently asked questions
What is Niacin (Flush)?
The flushing form of vitamin B3, used at higher doses for cholesterol/lipid management (raises HDL, lowers Lp(a)) — distinct from non-flushing niacinamide.
What is the suggested dose of Niacin (Flush)?
Start low (100 mg) and titrate; higher lipid doses need medical supervision. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Niacin (Flush) dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Niacin (Flush)?
Coach Cam sources Niacin (Flush) from vetted, top-rated brands on iHerb — use the buy link on this page.
Niacin (Flush) inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Niacin (Flush) is used for
Niacin (Flush) appears under 1 goal in the goal router.
Related Cardiovascular supplements
Where this goes next
Niacin (Flush) is the residual risk arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.